the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid.
.
.
.
. nightlife: bot wednesdays, belfast - may 16 2018 [photos]
.: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
marketwatch: "new migraine drugs have promise -- and a ,500 price tag."
.